Eli Lilly Co

General

Total Cases290

Active Cases3

Patents47

CourtsS.D. Indiana D. New Jersey D. Delaware

TypeOperating Company

Elite Ratings

PTAB

Ratings

Experience

Grade

Trend

DCT

L4

A

PTAB

L5

A

CAFC

L4

A

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
11/27/24	Eli Lilly & Co v. Qilu Pharmaceutical Co Ltd 2:24-CV-10802 ( D. NJ )	SEALED COMPLAINT against QILU PHARMA INC., QILU PHARMACEUTICAL CO., LTD. filed by ELI LILLY & COMPANY. (ECF Help Desk) (dam) (Entered: 11/27/2024)
11/27/24	Eli Lilly & Co v. Qilu Pharmaceutical Co Ltd 2:24-CV-10802 ( D. NJ )	SEALED COMPLAINT against QILU PHARMA INC., QILU PHARMACEUTICAL CO., LTD. filed by ELI LILLY & COMPANY. (ECF Help Desk) (dam) (Entered: 11/27/2024)
11/27/24	Eli Lilly & Co v. Qilu Pharmaceutical Co Ltd 2:24-CV-10802 ( D. NJ )	Corporate Disclosure Statement by ELI LILLY & COMPANY. (WALSH, LIZA) (Entered: 11/27/2024)
11/27/24	Eli Lilly & Co v. Qilu Pharmaceutical Co Ltd 2:24-CV-10802 ( D. NJ )	Corporate Disclosure Statement by ELI LILLY & COMPANY. (WALSH, LIZA) (Entered: 11/27/2024)
11/27/24	Eli Lilly & Co v. Qilu Pharmaceutical Co Ltd 2:24-CV-10802 ( D. NJ )	COMPLAINT against QILU PHARMA INC., QILU PHARMACEUTICAL CO., LTD. ( Filing and Admin fee $ 405 receipt number ANJDC-15838549) , Related Case Selected, filed by ELI LILLY & COMPANY. (Attachments: # [1] Exhibit 1, # [2] AO120 Form, # [3] Civil Cover Sheet)(WALSH, LIZA) (Entered: 11/27/2024)
11/27/24	Eli Lilly & Co v. Qilu Pharmaceutical Co Ltd 2:24-CV-10802 ( D. NJ )	COMPLAINT against QILU PHARMA INC., QILU PHARMACEUTICAL CO., LTD. ( Filing and Admin fee $ 405 receipt number ANJDC-15838549) , Related Case Selected, filed by ELI LILLY & COMPANY. (Attachments: # [1] Exhibit 1, # [2] AO120 Form, # [3] Civil Cover Sheet)(WALSH, LIZA) (Entered: 11/27/2024)
10/02/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	ORDER granting [45] Motion to Stay - Defendants' motion for stay of litigation pending decision on Defendants' Rule 12(b)(1) and 12(b)(6) motion to dismiss is granted. [Filing No. [45] .] In accordance with Plaintiffs' alternate request, the Court requires Defendants to provide regularly scheduled updates on the status of PNT2002's approval process to ensure that Plaintiffs have reasonable notice of the imminence of Defendants' commercial launch. (See Order For Additional Details.) Signed by Magistrate Judge Tim A. Baker on 10/02/2024. (AJG) (Entered: 10/02/2024) ORDER granting [45] Motion to Stay - Defendants' motion for stay of litigation pending decision on Defendants' Rule 12(b)(1) and 12(b)(6) motion to dismiss is granted. [Filing No. [45] .] In accordance with Plaintiffs' alternate request, the Court requires Defendants to provide regularly scheduled updates on the status of PNT2002's approval process to ensure that Plaintiffs have reasonable notice of the imminence of Defendants' commercial launch. (See Order For Additional Details.) Signed by Magistrate Judge Tim A. Baker on 10/02/2024. (AJG) (Entered: 10/02/2024)
09/24/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	DECLARATION of William A. McKenna re [55] Reply in Support of Motion by ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # [1] Exhibit 1-Study Details - Clinical Trials, # [2] Exhibit 2-Emaill Correspondence)(McKenna, William) (Entered: 09/24/2024)
09/24/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	REPLY in Support of Motion re [45] MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36) , filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 09/24/2024)
09/17/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	RESPONSE in Opposition re [45] MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36) [Plaintiffs' Response In Opposition To Defendants' Motion To Stay Discovery], filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # [1] Exhibit 1 - Lantheus Press Release, # [2] Exhibit 2 - PNT2002 ESMO Abstract)(Hidde, Kandi) (Entered: 09/17/2024) RESPONSE in Opposition re [45] MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36) [Plaintiffs' Response In Opposition To Defendants' Motion To Stay Discovery], filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # [1] Exhibit 1 - Lantheus Press Release, # [2] Exhibit 2 - PNT2002 ESMO Abstract)(Hidde, Kandi) (Entered: 09/17/2024)